Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomi...

por Lip, Gregory Y. H., Merino, Jose L., Banach, Maciej, Al‐Saady, Naab, Jin, James, Melino, Michael, Winters, Shannon M., Kozieł, Monika, Goette, Andreas
Publicado 2020

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

por Yi, B. Alexander, Freedholm, Debra, Widener, Nancy, Wang, Xiaohui, Simard, Emilie, Cullen, Constance, Al‐Saady, Naab M., Lepor, Norman E., Coulter, Sara, Lovern, Mark, Bloomfield, Dan
Publicado 2021

Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study

por Berlin, Sarah, Goette, Andreas, Summo, Luciana, Lossie, Janine, Gebauer, Alexander, Al-Saady, Naab, Calo, Leonardo, Naccarelli, Gerald, Schunck, Wolf-Hagen, Fischer, Robert, Camm, A.John, Dobrev, Dobromir
Publicado 2020

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSUR...

por Kozieł, Monika, Al-Saady, Naab, Hjortshøj, Søren P., Goudev, Assen, Huber, Kurt, Cohen, Ariel, Jin, James, Melino, Michael, Winters, Shannon M., Goette, Andreas, Lip, Gregory Y. H.
Publicado 2020